CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands | Common Stock | Additional Paid-in- Capital | Treasury Stock | Accumulated Other Comprehensive (Loss) Income | Accumulated Deficit | Total |
Beginning balance at Jan. 01, 2022 | $ 56 | $ 282,663 | $ (7,625) | $ 274 | $ (179,800) | $ 95,568 |
Beginning balance (in shares) at Jan. 01, 2022 | 52,960 | | | | | |
Increase (Decrease) in Stockholders' Equity | | | | | | |
Net Income (Loss) | | | | | 2,103 | 2,103 |
Issuance of shares in connection with stock option exercise | | 792 | | | | 792 |
Issuance of shares in connection with stock option exercise (in shares) | 533 | | | | | |
Issuance of shares in connection with restricted stock units vesting | $ 1 | (1) | | | | |
Issuance of shares in connection with restricted stock units vesting (in shares) | 519 | | | | | |
Issuance of stock awards to consultants | | 81 | | | | 81 |
Issuance of stock awards to consultants (in shares) | 10 | | | | | |
Issuance of shares in connection with BOD Fees | | 6 | | | | 6 |
Issuance of shares in connection with ESPP | | 431 | | | | 431 |
Issuance of shares in connection with ESPP (in shares) | 45 | | | | | |
Officers and directors stock purchase plan | | 23 | | | | 23 |
Officers and directors stock purchase plan (in shares) | 3 | | | | | |
Share-based compensation | | 4,225 | | | | 4,225 |
Unrealized gain (loss) on deferred compensation trust assets | | | | (34) | | (34) |
Effect of changes in foreign currencies | | | | 20 | | 20 |
Ending balance at Apr. 02, 2022 | $ 57 | 288,220 | (7,625) | 260 | (177,697) | 103,215 |
Ending balance (in shares) at Apr. 02, 2022 | 54,070 | | | | | |
Increase (Decrease) in Stockholders' Equity | | | | | | |
Net Income (Loss) | | | | | 4,118 | 4,118 |
Issuance of shares in connection with stock option exercise | | 136 | | | | 136 |
Issuance of shares in connection with stock option exercise (in shares) | 70 | | | | | |
Issuance of shares in connection with restricted stock units vesting (in shares) | 220 | | | | | |
Issuance of shares in connection with BOD Fees | | 6 | | | | 6 |
Officers and directors stock purchase plan | | 4 | | | | 4 |
Share-based compensation | | 771 | | | | 771 |
Unrealized gain (loss) on deferred compensation trust assets | | | | (100) | | (100) |
Effect of changes in foreign currencies | | | | 104 | | 104 |
Ending balance at Jul. 02, 2022 | $ 57 | 289,137 | (7,625) | 264 | (173,579) | 108,254 |
Ending balance (in shares) at Jul. 02, 2022 | 54,360 | | | | | |
Beginning balance at Dec. 31, 2022 | $ 57 | 297,265 | (7,625) | 1,126 | (180,751) | 110,072 |
Beginning balance (in shares) at Dec. 31, 2022 | 54,693 | | | | | |
Increase (Decrease) in Stockholders' Equity | | | | | | |
Net Income (Loss) | | | | | 1,051 | 1,051 |
Issuance of shares in connection with stock option exercise | $ 1 | 1,523 | | | | 1,524 |
Issuance of shares in connection with stock option exercise (in shares) | 972 | | | | | |
Issuance of shares in connection with restricted stock units vesting | $ 1 | | | | | 1 |
Issuance of shares in connection with restricted stock units vesting (in shares) | 495 | | | | | |
Issuance of shares in connection with BOD Fees | | 6 | | | | 6 |
Issuance of shares in connection with BOD Fees (in shares) | 1 | | | | | |
Issuance of shares in connection with ESPP | | 221 | | | | 221 |
Issuance of shares in connection with ESPP (in shares) | 42 | | | | | |
Share-based compensation | | 4,170 | | | | 4,170 |
Unrealized gain (loss) on deferred compensation trust assets | | | | 24 | | 24 |
Ending balance at Apr. 01, 2023 | $ 59 | 303,185 | (7,625) | 1,150 | (179,700) | 117,069 |
Ending balance (in shares) at Apr. 01, 2023 | 56,203 | | | | | |
Beginning balance at Dec. 31, 2022 | $ 57 | 297,265 | (7,625) | 1,126 | (180,751) | $ 110,072 |
Beginning balance (in shares) at Dec. 31, 2022 | 54,693 | | | | | |
Increase (Decrease) in Stockholders' Equity | | | | | | |
Issuance of shares in connection with stock option exercise (in shares) | | | | | | 1,251 |
Ending balance at Jul. 01, 2023 | $ 59 | 306,568 | (8,672) | 1,174 | (180,371) | $ 118,758 |
Ending balance (in shares) at Jul. 01, 2023 | 56,914 | | | | | |
Beginning balance at Apr. 01, 2023 | $ 59 | 303,185 | (7,625) | 1,150 | (179,700) | 117,069 |
Beginning balance (in shares) at Apr. 01, 2023 | 56,203 | | | | | |
Increase (Decrease) in Stockholders' Equity | | | | | | |
Net Income (Loss) | | | | | (671) | (671) |
Issuance of shares in connection with stock option exercise | | 446 | | | | 446 |
Issuance of shares in connection with stock option exercise (in shares) | 279 | | | | | |
Issuance of shares in connection with restricted stock units vesting (in shares) | 431 | | | | | |
Issuance of shares in connection with BOD Fees | | 5 | | | | 5 |
Issuance of shares in connection with BOD Fees (in shares) | 1 | | | | | |
Share-based compensation | | 2,937 | | | | 2,937 |
Stock repurchase | | (5) | (1,047) | | | (1,052) |
Unrealized gain (loss) on deferred compensation trust assets | | | | 24 | | 24 |
Ending balance at Jul. 01, 2023 | $ 59 | $ 306,568 | $ (8,672) | $ 1,174 | $ (180,371) | $ 118,758 |
Ending balance (in shares) at Jul. 01, 2023 | 56,914 | | | | | |